DB15859InvestigationalVaccines
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX... Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses.
- Code names
- NasoVAX
What you can answer from here — as of April 23, 2025
Which companies are running trials of NasoVAX, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account